Swedbank AB Invests $7.48 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Swedbank AB bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 22,400 shares of the company’s stock, valued at approximately $7,477,000.

A number of other hedge funds have also added to or reduced their stakes in MEDP. DT Investment Partners LLC acquired a new position in shares of Medpace during the 2nd quarter worth about $41,000. Ashton Thomas Securities LLC bought a new stake in Medpace during the third quarter worth about $37,000. Ashton Thomas Private Wealth LLC acquired a new position in Medpace during the second quarter valued at approximately $52,000. Capital Performance Advisors LLP bought a new position in Medpace in the third quarter valued at approximately $46,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Medpace during the 2nd quarter worth approximately $61,000. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on MEDP shares. Robert W. Baird increased their price objective on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a report on Monday. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and decreased their price objective for the company from $415.00 to $345.00 in a research report on Wednesday, September 25th. William Blair restated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and cut their target price for the company from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and a consensus price target of $380.56.

Medpace Trading Down 0.8 %

Shares of NASDAQ MEDP opened at $335.21 on Wednesday. The business’s 50 day moving average is $339.37 and its 200-day moving average is $372.21. The firm has a market cap of $10.42 billion, a P/E ratio of 29.35, a price-to-earnings-growth ratio of 1.87 and a beta of 1.37. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter last year, the firm earned $2.22 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. Analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.